Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director.
- DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director.
- “We are very excited to welcome Avinash to Trinity Biotech, where he will be instrumental in advancing our mission of introducing intelligent wearable biosensors, including CGMs, into markets all around the globe.
- Mr. Kale, a seasoned MedTech R&D, PMO & Innovation leader, with extensive global industry experience recently joined Trinity Biotech’s team in Ireland, from Philips Healthcare, The Netherlands.
- Mr. Kale holds a degree in Electronics and Telecommunications from Pune University, India, and has successfully completed the Leading Digital Transformation in Healthcare Executive Programme from Harvard Medical School.